Advertisement


Stephen M. Ansell, MD, PhD, on Hematologic Malignancies: Immunotherapy Update

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Advertisement

Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses integrating immune checkpoint inhibitors, improving efficacy, and reducing toxicity when treating blood cancers.



Related Videos

Prostate Cancer
Immunotherapy

James L. Gulley, MD, PhD, on Prostate Cancer: Expanding Immunotherapy Options

James L. Gulley, MD, PhD, of the National Cancer Institute, discusses combined treatment approaches showing early evidence of clinical activity: agents such as vaccines or PARP inhibitors that can initiate an immune response, paired with agents such as checkpoint inhibitors that can facilitate the activity of tumor-directed immune cells.

Lung Cancer
Immunotherapy

Roy S. Herbst, MD, PhD, on Personalized Immunotherapy for Lung Cancer: Expert Perspective

Roy S. Herbst, MD, PhD, of the Yale School of Medicine, summarizes a session that included discussion of the mechanisms of immunotherapies, biomarkers for activity of these agents, overcoming resistance, and using treatment combinations.

Solid Tumors
Immunotherapy

Jeffrey M. Lemons, MD, on Solid Tumors: Safety Data on SBRT and Immunotherapy

Jeffrey M. Lemons, MD, of the University of Chicago, discusses early safety and efficacy findings from a small study on pembrolizumab and multiorgan-site ablative stereotactic body radiotherapy in patients with advanced solid tumors (Abstract 20).

Bladder Cancer
Immunotherapy

Joaquim Bellmunt, MD, PhD, on Bladder Cancer: The Future of Immunotherapies

Joaquim Bellmunt, MD, PhD, of Dana-Farber Cancer Institute, discusses refining treatment choices with new combinations and sequencing strategies.

Kidney Cancer
Immunotherapy

Sumanta K. Pal, MD, on Renal Cancer Immunotherapy: Latest Developments

Sumanta K. Pal, MD, of the City of Hope, discusses immunotherapy as a front-line treatment for kidney cancer and the strategy of VEGF blockade with immunotherapy, which is emerging as a possible treatment modality.

Advertisement

Advertisement




Advertisement